For example, KRAS, BRAF and PIK3CA may have prognostic values in CRC [8], mutation detection of combination of KRAS, BRAF and PIK3CA could contribute to predict the response of CRC patients to EGFR pathway inhibitors [9]. This evidence concerns the gene EGFR and colorectal carcinoma.